Other striking factors include initiation of G-CSF treatment, that is, the timing of G-CSF treatment might influence its neuroprotective effect; different dosages have been used both in ischemic stroke and neonatal HIE animal models, ranging from 10 to 250 μg/kg for subcutaneous injection and 5 to 60 mg/kg for intravenous injection [43, 61, 78]; route of administration varies according to each study; and duration of treatment ranges from 3 to 10 days [64, 80, 84]. Here, CSF3 is linked to ischemic stroke.